Additionally, in vivo studies are essential to assess the safety, efficacy, and biological interactions of visfatin-neutralizing antibodies in a more complex system, especially given the complexities of osteoporosis and the potential for unforeseen effects. This evidence concerns the gene NAMPT and osteoporosis.